A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse

Molecular Carcinogenesis

Volumn 27, Issue 1, 2000, Pages 24-33

  Trempus, Carol S ^a   Bishop, W Robert ^b   Njoroge, F George ^b   Doll, Ronald J ^b   Battalora, Michael Stj ^a   Mahler, Joel F ^a   Haseman, Joseph K ^a   Tennant, Raymond W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Farnesylation; Phorbol ester; Skin tumorigenesis

Indexed keywords

ACETONE; PHORBOL ESTER DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SCH 56582; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EPIDERMIS HYPERPLASIA; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; KERATINOCYTE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PROCESSING; SKIN PAPILLOMA; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BENZAZEPINES; CROSSES, GENETIC; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; GENES, RAS; GLOBINS; HOMOZYGOTE; HYPERPLASIA; KERATINOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, TRANSGENIC; PAPILLOMA; PROMOTER REGIONS (GENETICS); SKIN; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS;

ANIMALIA; MUS MUSCULUS;

EID: 0033960688     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(200001)27:1<24::AID-MC5>3.0.CO;2-M     Document Type: Article

References (33)

1. Gibbs JB. Ras C-terminal processing enzymes - new drug targets? Cell 1991;65:1-4.
2. Gibbs JB, Kohl NE, Koblan KS, et al. Farnesyltransferase inhibitors and anti-ras therapy Breast Cancer Res Treat 1996;38:75-83.
3. Kelloff GJ, Lubet RA, Fay JR, et al. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prevent 1997;6:267-282.
4. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: Targeting simply ras? Biochim Biophys Acta 1997;1333:F51-F71.
5. Khosravi-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: Key to ras function and cancer intervention? Cell Growth Differ 1992;3:461-469.
6. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992;89:6403-6407.
7. Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice Proc Natl Acad Sci USA 1994;91: 9141-9145.
8. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Genet 1995; 1:792-797.
9. Sun J, Qian Y, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 1995;55:4243-4247.
10. Barrington RE, Subler MA, Rands E, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998;18:85-92.
11. Liu M, Bryant MS, Chen J, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and WAP-ras transgenic mice Cancer Res 1998; 58:4947-4956.
12. Norgaard P, Law B, Joseph H, et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 1999;5:35-42.
13. Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with rho activity. Mol Cell Biol 1995;15: 6613-6622.
14. Lobell RB, Kohl NE. Pre-clinical development of farnesyltransferase inhibitors. Cancer Met Rev 1998;17:203-210.
15. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995;55:5302-5309.
16. Leder A, Kuo A, Cardiff RD, Sinn E, Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA 1990;87:9178-9182.
17. Tennant RW, Spalding J, French JE. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res 1996;36:119-127.
18. Cannon RE, Spalding JW, Trempus CS, et al. Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol Carcinog 1997;20:108-114.
19. Trempus CS, Mahler JF, Ananthaswamy HN, Loughlin SM, French JE, Tennant RW. Photocarcinogenesis and susceptibilty to UV radiation in the v-Ha-ras transgenic Tg.AC mouse. J Invest Dermatol 1998;111:445-451.
20. Njoroge FG, Vibulbhan B, Rane DF, et al. Structure-activity relationship of 3-substituted N-(pyndinylacetyl)-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b] pyridin-11-ylidene)-piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds. J Med Chem 1997;40:4290-4301.
21. Hansen LA, Tennant RW. Focal transgene expression associated with papilloma development in v-Ha-ras transgenic Tg.AC mice. Mol Carcinog 1994;9:143-154.
22. Morris RJ, Tacker KC, Baldwin JK, Fisher SM, Slaga TJ. A new medium for adult murine epidermal cells: Application to experimental carcinogenesis. Cancer Lett 1987;34: 297-304.
23. Trempus CS, Haseman JK, Tennant RW. Decreases in phorbol ester-induced papilloma development in v-Ha-rss transgenic Tg.AC mice during reduced gene dosage of bcl-2. Mol Carcinog 1997;20:68-77.
24. Snedecor GW, Cochran WG. Statistical methods. Ames, Iowa: Iowa State University Press; 1980.
25. Robles AI, Rodriguez-Puebla ML, Glick AB, et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998;12:2469-2474.
26. Smith MK, Trempus CS, Gilmour SK. Co-operation between follicular ornithme decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Carcinogenesis 1998;19:1409-1415.
27. vy) agouti allele on skin tumorigenesis and humoral hypercalcemia in v-Ha-ras transgenic Tg.AC mice. Carcinogenesis 1998;19:1837-1845.
28. Hansen LA, Tennant RW. Follicular origin of epidermal papillomas in v-Ha-ras transgenic Tg.AC mouse skin. Proc Natl Acad Sci USA 1994;91:7822-7826.
29. Hansen LA, Trempus CS, Mahler JF, Tennant RW. Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice. Carcinogenesis 1996;17:1825-1833.
30. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmac Ther 1992;54:63-128.
31. Binder RL, Johnson GR, Gallagher PM, Stockman SL, Sundberg JP, Conti CJ. Squamous cell hyperplastic foci: Precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen. Cancer Res 1998;58:4314-4323.
32. Slaga TJ, Fischer SM, Nelson K, Gleason GL. Studies on the mechanism of skin tumor promotion: Evidence for several stages of promotion. Proc Natl Acad Sci USA 1980;77: 3659-3663.
33. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.